Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brivanib with Cetuximab and Irinotecan in K-Ras Wildtype MCRC
NCT00594984Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- May 2008
- Primary completion
- Dec 2012
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial of brivanib alaninate in metastatic colorectal cancer (mCRC) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Pharmacokinetics and Safety and tolerability. Started May 2008; status: completed.
02
Drugs
brivanib alaninate
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT00594984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00594984.